

Key Information

Headquarters-Europe

AirInSpace B.V.
Delftech Park 26
2628 XH Delft, The Netherlands
Phone: +31 (15) 2600 930
Fax: +31 (15) 2600 931

AirInSpace S.A.S.

Zone d'activité du Pas du Lac
10 avenue Ampère - Bâtiment B2
78180 Montigny Le Bretonneux, France
Phone: +33 1 30 07 01 01
Fax: +33 1 30 07 01 02

Headquarters-United States

AirInSpace Inc.

46179 Westlake Drive, Suite 330
Sterling, VA 20165
Phone: +1 703 621 0671
Fax: +1 703 621 4535

Website www.airinspace.com

Investors Matignon Technologies,
Oddo AM, Baring Vostok
Capital Partners (BVCP)

Sector Medical Devices
General Hospital

Employees 30

Investor Contact: Laurent Fullana, CEO
AirInSpace
+31 (15) 2600 930

Media Contact: Ronald Trahan, APR
President
Ronald Trahan Asso. Inc.
+1 508 359 4005, x108

Leadership Team

Laurent Fullana
Chief Executive Officer

Wade Tetsuka
President, U.S. Operations

Vance Bergeron, PhD
Chief Scientific Officer

Anthony Lecomte
Chief Financial Officer

Patrick Aubert
Director, Air Transportation Market

Laurent Descotes, PhD
Director, Product Development &
Industrialization

Stephane Ortu
Dir., Business Unit Healthcare France

Advisory Board

Jean Michel Broun
Senior Partner and a Director of Baring
Vostok Capital Partners (Moscow)

Eliane Gluckman, MD, PhD
Medical Coord., Dept. of Hematology &
Oncology, Hospital Saint-Louis (Paris)

John H. Markels, PhD
Vice President of Operations in Europe,
Middle East and Africa for Merck & Co.

Eckhard Polzer
Former Chairman and Chief Executive
Officer of Dornier Medical International

AirInSpace owns a patented core technology, HEPA/MD™—the next generation of the Company's initial Plasmer™ platform—that inactivates lethal airborne microorganisms. Developed initially for use in Russia's MIR space station, the AirInSpace technology is in routine use today on the International Space Station (ISS). AirInSpace owns the exclusive rights to this one-of-a-kind technology, which shows up to 99.999% *single-pass* inactivation of airborne microorganisms. HEPA/MD technology is highly scalable and is being adapted by AirInSpace and its partners to a wide range of applications.

The Company's first potential 'homerun' product in the U.S., based on HEPA/MD technology, is its FDA cleared *PlasmairT2006* by AirInSpace mobile device that captures and inactivates biological particles from the air for medical purposes. Conventional HEPA (High Efficiency Particulate Air) filters are the most common airborne-decontamination method used in hospitals, *but they do not inactivate the pathogens they trap* and can therefore serve as a reservoir for incubating more pathogens that can release into the air to pose a lethal risk to patients, staff and maintenance personnel. Indeed, hospital-acquired (*nosocomial*) infections affect nearly one in 10 patients *in developed countries*. New regulations are being imposed to control airborne contamination levels, requiring hospitals to undertake massive renovations to upgrade their ventilation systems. Alternatively, hospitals are finding unprecedented success with deployment of *PlasmairT2006* mobile units.

In addition to the hospital market (\$1.8 billion opportunity), AirInSpace has developed applications for other markets, such as air transportation. On longer flights when cabin air is re-circulated for hours, concentrations of bio-contaminants may rise to dangerous levels, and passengers are exposed to a higher risk of cross-infection. The onboard SARS transmission in 2003 is an alarming example. AirInSpace's technology is now being installed in the main cabin ventilation systems of a major business jet manufacturer.

The Company believes its HEPA/MD technology is superior to all available and known air decontamination technologies. HEPA/MD technology offers critically unique advantages: (1) Microbe collection *and* inactivation; and (2) Physical efficiency (easy to get air through the system, no 'clogging', which means it is energy-friendly and less noisy). Nearly three dozen independent studies at prestigious academic labs such as Harvard School of Public Health (Boston) have tested HEPA/MD technology's efficacy.



AirInSpace's first potential 'homerun' product is *PlasmairT2006*, a mobile unit used by 100+ hospitals throughout France.

Germicidal Efficacy Up to 99.999% rate

PlasmairT2006 inactivates harmful and resistant infectious microorganisms.

Cost-Effective

New regs require action by hospital

Hospitals are under intense pressure to control airborne contamination. A mobile PlasmairT2006 unit offers an economical, reliable, and immediate solution.

Special Issue:
Airborne Transmission

Recommended practices for surveillance: Association for Professionals in Infection Control and Epidemiology (APIC), Inc.
T. B. Cox, G. C. Papanicolaou, J. P. Fine, M. J. Tenover, and P. S. Tarr

- 1. Influenza vaccination of health care workers: Policies and practices of hospitals in a community setting
J. A. Szilagyi, P. A. Coombs, M. P. Heffernan, S. B. Klevor, M. L. Madigan, A. Jenkins, and V. A. Chittenden
- 2. Working with symptoms of a respiratory infection: Staff who care for high-risk individuals
S. Lurie, B. Goldstein, B. Green, and P. H. Wesson
- 3. A survey of Alberta physicians' use of and attitudes toward face masks and face shields in the operating room setting
B. Dale, D. Spady, and S. D. Forgie
- 4. Evaluation of a new mobile system for protecting immune-suppressed patients against airborne contamination
J. L. Ford, J. P. Carrique, A. Fischer, M. M. Bennett, S. Chiller, N. Landstet, and V. Bergeron
- 5. A survey of human cases of H5N1 avian influenza reported by the WHO before June 2006 for infection control
H. H. Chen, J. W. Chen, H. Dai, and K. K. Sun
- 6. Isolation status and voice prompts improve hand hygiene
S. P. Srinivasan, P. Farthing, P. Srinivasan, S. Lane, and P. B. Jorgensen
- 7. Tanning in prisons—Not such a pretty picture
P. B. McQuinn, C. A. Allen, and D. W. Hooper
- 8. On-site influenza vaccination arrangements improved influenza vaccination rate of employees of a tertiary hospital in Singapore
H. Yang, L. Tan, and Y. Tan
- 9. Pandemic influenza preparedness: A survey of businesses
P. W. Leung, P. Chen, S. K. Lam, and P. B. Jorgensen
- 10. Absence of pharyngeal shedding of vaccine following smallpox vaccination
T. H. Patel, J. H. Patel, P. Wright, and R. F. Edwards
- 11. A modified "cover your cough" campaign prevents exposures of employees to pertussis at a children's hospital
A. Chhabria, S. P. Purohit, B. Purohit, T. Barlow, K. S. Joshi, P. H. and S. L. Laxmi

September 2007
Volume 35
Number 7

Official Publication of
APIC

W. A. Mosby
9780 1550 4033